Lowest Price Guaranteed
Slides
90
Last Updated
July 2026
View Count
14119
The global SARM1 inhibitor market size is estimated to be worth USD 5 million in 2033 and is expected to reach USD 727 million by 2040, growing at a CAGR of 102% during the forecast period.
To learn more about this report, request a free sample copy
Neurological disorders represent a significant and escalating global health concern which is considered a substantial portion of the overall disease burden worldwide. According to a United Nations report, nearly 1 billion people around the world suffer from various neurological conditions such as Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, Peripheral Neuropathies and Amyotrophic Lateral Sclerosis. This high prevalence of neurological disorders has placed significant strain on healthcare systems financially and resource-wise. A WHO report states that the U.S. alone spends more than USD 655 billion every year on neurological disorders. Interestingly, many therapies are available in the market for treating such diseases. However, the existing treatment’s limited efficacy or insufficiency to treat certain conditions related to axonal degeneration has created a need for highly effective therapeutics targeting neurological disorders.
Consequently, including these factors and the rising incidence of neurological disorders has expanded the potential growth of the SARM1 inhibitor market. Sterile Alpha and toll/Interleukin-1 Receptor Motif-Containing 1 (SARM1), a NADase enzyme, has emerged as a pivotal factor in triggering axonal degeneration which is a fundamental characteristic observed in numerous neurodegenerative disorders. Additionally, several drug developers are exploring SARM1 inhibitors as promising therapeutic candidates in order to address neurological disorders. The evaluations cover a range of preclinical investigations and early phases of clinical trials at a global scale. Notably, the first product is expected to be commercially launched in 2033. Besides these factors, the SARM1 inhibitors market is expected to grow driven by the potential benefits of SARM1 inhibitors, promising preclinical data, continuous advancements, mounting research, and innovation in the SARM1 targeting therapeutics in this domain till 2040.
The market research report presents an in-depth analysis of the various companies that are engaged in the global market of SARM1 inhibitors, across different segments, as defined in the table below:
| Key Report Attribute | Details | |
| Historical Trend | NA | |
| Forecast Period | Till 2040 | |
| Market Size in 2033 | USD 5 Million | |
| Market Size in 2040 | USD 727 Million | |
| CAGR (Till 2040) | 102% | |
| By Target Indications |
|
|
| Type of Type of Molecule |
|
|
| Key Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
One of the key objectives of this market report was to estimate the current market size, opportunity, and future growth potential of the SARM1 inhibitor market, over the forecast period. Based on multiple parameters, likely adoption trends, and through primary validations, we have provided an informed estimate of the market evolution during the forecast period till 2040.
The market report also features the likely distribution of the current and forecasted opportunity within the SARM1 inhibitor market across various segments, such as type of target indications (multiple sclerosis, peripheral, central and ocular nervous system disorders, peripheral neuropathies, glaucoma, and amyotrophic lateral sclerosis), type of molecule (small molecules and biologics), and key geographical regions (North America, Europe and Asia Pacific, Latin America, Middle East, North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD unless otherwise specified.
The global SARM1 inhibitor market is segmented into various target indications such as Multiple Sclerosis, Peripheral, Central, and Ocular Nervous System Disorders, Peripheral Neuropathies, Glaucoma, and Amyotrophic Lateral Sclerosis. Based on the target indications, Multiple Sclerosis captures the largest 39% of the SARM1 inhibitor market share and is likely to lead the market segment by 2040. The growing incidence of multiple sclerosis, a complex neurological condition, worldwide is inflating the demand for effective treatment and SARM1 offers a novel therapeutic approach that targets neurodegeneration which potentially addresses an unmet requirement in Multiple Sclerosis treatment. Besides, Amyotrophic Lateral Sclerosis is anticipated to elevate the market comparatively at a higher CAGR of 100.2% over this projection period.
Based on the type of molecules, the SARM1 inhibitor market is bifurcated into Small Molecules and Biologics. According to market research, small molecules will likely capture the majority (95%) of the market share by 2040. Small molecules are specifically designed to target the SARM1 protein which is accountable for various neurodegenerative disorders, significantly lift the market growth, and are projected to drive the market at 100.5% CAGR by 2040.
This segment highlights the distribution of the SARM1 inhibitor market across various geographies, such as North America, Europe, Asia-Pacific Latin America, Middle East and North Africa. According to our projections, North America is anticipated to dominate the global market for SARM1 inhibitors with 67% of the share in terms of revenue by 2040. Driven by factors such as a surge in research and development activities for drug discovery and the rising initiative in developing novel therapies, the market is continuously thriving in the region. Europe is likely to grow at a higher CAGR of 141.7% during the projection period 2033-2040.
The “SARM1 Inhibitor Market: Industry Trends and Global Forecasts, till 2040” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in the development of SARM1 inhibitors as therapeutics. The market report highlights the efforts of several manufacturers of small molecules and biologics in this rapidly emerging segment of the pharmaceutical industry. Key takeaways from the market size, competitive landscape, and geographical regions in the SARM1 inhibitor market report are briefly discussed below.
Around 50% of the drug developers active in this market are non-industry players who are constantly exploring the potential of a wide range of biologic and small-molecule drugs to inhibit SARM1 pathways. Furthermore, over 30 grants have been awarded in the last five years to several entities to strengthen ongoing endeavors in R&D of the SARM1 targeting therapeutics. In addition, most organizations are based in North America and nearly 37% of developers are headquartered in the U.S. These organizations actively partake in scientific conferences, publish journals as well as articles to advance the capability and understanding of SARM1 inhibition. Interestingly, in the last few years, approximately 30% of the total articles were published on SARM1 and its targeting therapies.
Over the past few years, the SARM1 inhibitor market has been witnessing a rising investment in research and drug development. A large number of pharmaceuticals, academic institutions, and research organizations are constantly investing in the development of SARM1 inhibitors. For example, Washington University, Umass Chan, and other prominent research institutions are investigating a diverse range of drug candidates in preclinical studies and exploring the therapeutic potential of SARM1 inhibition across multiple neurological conditions. Besides, in April 2024, Asha Therapeutics announced to conduct preclinical studies to develop ASHA-624 an experimental therapy planned to inhibit the activity of the SARM1 protein, as a promising disease-modifying treatment for amyotrophic lateral sclerosis (ALS).
Additionally, with regard to SARM1 inhibition research, the trend of personalized medicine is gaining traction in the market. Precision medicine involves customizing treatment to individual patient characteristics like genetics, biomarkers, or disease subtypes. By analyzing these genetic factors, researchers seek to pinpoint individuals who are most responsive to SARM1 inhibition.
In respect of regional insights, over 37% of SARM1 inhibitor developers are based in North America, stimulating market growth and is anticipated to dominate the global market for SARM1 inhibitors. With the rising prevalence of neurological disorders in the U.S. Several biotech companies and institutions in North America are availing of the growing opportunities in drug discovery by conducting a large number of clinical trials, research, and innovation for SARM1 inhibitors therapies and filing for grants and patents. It is worth noting that Washington University received the highest (64%) of grants above all the organizations. Additionally, around 24% of the U.S.-based affiliated universities constantly publish research papers and scientific articles related to SARM1 and its targeting therapies which contribute to the region’s leading position.
Examples of key companies engaged in the SARM1 inhibitor industry (which have also been profiled in this market report; the complete list of companies is available in the full report) include Disarm Therapeutics, Nura Bio, and Washington University. This market report includes an easily searchable excel database of all the companies who are engaged in the evaluation of SARM1 inhibitors as therapeutics.
 |
 |
 |
 |
 |
 |
 |
 |
 |
In the past few years, the market for SARM1 Inhibitors has been blooming. Several ongoing innovations and developments are projected to boost market potential. These developments, even if they took place post the release of our market report, substantiate the overall trends that have been outlined in our SARM1 inhibitor market analysis.